Compare VHC & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | XTNT |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 82.6M |
| IPO Year | 1999 | N/A |
| Metric | VHC | XTNT |
|---|---|---|
| Price | $18.01 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 27.2K | ★ 241.1K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $106,000.00 | ★ $133,083,000.00 |
| Revenue This Year | N/A | $15.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $69.41 |
| Revenue Growth | ★ 2020.00 | 16.88 |
| 52 Week Low | $5.01 | $0.34 |
| 52 Week High | $29.00 | $0.95 |
| Indicator | VHC | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 56.10 |
| Support Level | $16.32 | $0.75 |
| Resistance Level | $19.16 | $0.81 |
| Average True Range (ATR) | 1.78 | 0.07 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 32.61 | 60.30 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.